EFG
NVO

Everest Financial Group’s Novo Nordisk NVO Stock Holding History

Everest Financial Group’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$228K Sell
4,766
-1,358
-22% -$58.3K 0.03% 194
2026
Q1 		$225K Buy
+6,124
New +$290K 0.04% 189

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Everest Financial Group's NVO Position: Q2 2026 in Review

Everest Financial Group reduced its Novo Nordisk (NVO) stake by 22% in Q2 2026, selling an estimated $58.3K and leaving 4,766 shares worth $228K. The position accounts for 0.03% of the portfolio, ranked #194.

Everest Financial Group first reported a position in NVO in Q1 2026 and has held it in 2 quarters since. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Everest Financial Group held 4,766 shares of Novo Nordisk worth $228K as of Q2 2026.
  • Everest Financial Group sold 1,358 Novo Nordisk shares in Q2 2026, an estimated $58.3K.
  • Novo Nordisk made up 0.03% of Everest Financial Group's portfolio in Q2 2026, its #194 holding.
  • Everest Financial Group first reported a position in Novo Nordisk in Q1 2026 and has held it in 2 quarters since.
  • 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Everest Financial Group's 13F filing for Q2 2026, filed 10 Aug 2026.